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Abstract
Multi-parametric magnetic resonance imaging is
increasingly being recommended as standard imaging
modality for prostate cancer diagnosis and staging. It
comprises structural T2 and T1 sequences supplemented
by functional imaging techniques, i.e. diffusion-
weighted, dynamic contrast enhanced and spectroscopic
imaging. Pre-biopsy multi-parametric magnetic
resonance imaging is recommended for both detection
and staging as it avoids biopsy artefact, and when
normal, has a negative predictive value of 95% for
significant cancer. Magnetic resonance imaging-guided
prostate biopsy targets only area(s) considered to be
suspicious for prostate cancer, hence resulting in
improved accuracy. Dynamic contrast enhancing helps in
the detection of cancer and for the assessment of extra-
capsular extension, distal urethral sphincter and seminal
vesicles involvement. The role of multi-parametric
magnetic resonance imaging in follow-up of patients on
active surveillance is also increasingly recognised. Its role
is now further expanded to facilitate targeted therapies.
This review focuses on the evolving role of multi-
parametric magnetic resonance imaging in diagnosis
and management of prostate cancer.
Keywords: Magnetic resonance imaging, Prostate,
Cancer, Multi-parametric.
Introduction
Prostate cancer is one of the most common cancers and
leading causes of death in industrialised nations.1,2 The
classical diagnostic tools for detecting prostate cancer
are prostate specific antigen (PSA), digital rectal
examination (DRE) and trans-rectal ultrasound (TRUS)-
guided biopsy. Imaging has a pivotal part in prostate
cancer treatment selection and planning.3 In the recent
years, magnetic resonance imaging (MRI) has taken up a
greater role in the diagnostic algorithm of prostate
cancer.
MRI equipment and technical considerations
Compared with the conventional MRI using phased- array
coil, combining the endo-rectal coil provides state-of-the-
art imaging for staging prostate cancer with excellent
signal quality and improved spatial resolution.3,4 Higher
magnetic fields at 3-Tesla provides a twofold increase in
signal-to-noise ratio (SNR), shorter overall scan time and
increase in spatial, temporal and spectroscopic resolution
with better structural and functional detail compared to
low field strength (e.g. 1.5 T) MRI.5
Multi-parametric (mp) MRI
Multi-parametric MRI (mp-MRI) includes combination of
high-resolution T2-weighted images assessing the
anatomy and at least two functional MRI techniques, i.e.
diffusion weighted imaging (DWI) and magnetic
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Table: Different components of multi-parametric (mp) MRI.
Modality                              Principle                                      Clinical utility
MRI: Magnetic resonance imaging
T1W: T1-weighted
BPH: Benign prostatic hyperplasia.
T 2 weighted
images
Diffusion
weighted images
Dynamic Contrast
enhanced
MR spectroscopy
Fast spin echo
sequence with
long repetition
time and long
echo time
Brownian motion
of water molecules
in tissues
Micro-vascular
properties of
tumour
angiogenesis
Biochemical and
metabolic status of
tissues 
Cell membrane
turnover
Primary sequence of visualization of
structures in and out of the gland.
Best depiction of prostate zonal anatomy
(Detection, localization and staging of
prostate cancer). 
Cancer is low in signal.
Sensitive but not specific for prostate cancer. 
Detection of prostate cancer foci 
Rapid cell turnover with reduced
extracellular space
Low signal intensity on ADC (apparent
diffusion coefficient) maps.
Discriminatory power to distinguish b/w
high vs. low Gleason grade disease
Adds specificity and lesion
characterization.
Uses T1W sequences
Differentiates carcinomatous foci from
BPH nodules.
Expressed by enhancement pattern i.e.
early enhancement and early washout
Adds sensitivity for cancer detection
Detect malignancy in peripheral zone.
Increased choline/ citrate ratio
Adds specificity and lesion
characterization. 
resonance spectroscopic imaging (MRSI), adding
specificity and lesion characterisation.6 Perfusion-based
dynamic contrast-enhanced MRI (DCE-MRI) has high
sensitivity in cancer detection6 (Table). De Rooij M. et al. in
a meta-analysis found mp-MRI to have high specificity,
negative predictive value (NPV) and sensitivity for
detecting prostate cancer.7
Morphological / Anatomical information
The detection of prostate cancer depends upon the type
of image sequence used. Higher resolution T2-weighted
(T2W) MRI imaging offers best information about
prostatic capsule and zonal anatomy, hence used for
detection, localisation and staging of prostate cancer7
(Figure-1).
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T1W: T1-weighted. T2W: T2-weighted
Figure-1: Normal Prostate; a) T1W image-prostate gland is iso-intense to the surrounding muscles. b) T2W image- Prostate gland is slightly hyper-intense to the surrounding muscles
especially the peripheral zone.
T1W: T1-weighted. T2W: T2-weighted. FATSAT: Fat saturation
Figure-2: Tumour nodule. a) FATSAT -T1W image shows an iso-intense nodule at the right lateral zone of the prostate gland which is difficult to differentiate from the normal prostate
gland due to similar signal intensity, but appears as an asymmetrical bulge. b) T2W image; re-demonstration of an iso-intense nodule in the right lateral aspect of the prostate gland.
This is relatively hyper-intense to the surrounding muscles but is still hypo-intense to the peripheral zone.
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T1W: T1-weighted. T2W: T2-weighted
Figure-3: a) T1W image of the prostate shows a nodule occupying the left half of the prostate gland. As this is iso- intense to the prostate gland, therefore, difficult to appreciate on
T1W images. A tiny hyper-instense focus at the right lateral aspect of the prostate represents hemorrhage due to recent biopsy. b) T2W image show the nodule in left lateral aspect of
the prostate gland which is slightly hyper-intense to the surrounding muscles but is still hypo-intense to the normal prostate gland.
MR: Magnetic resonance.
Figure-4: a) Diffusion weighted image (DWI) show a hyper intense focus corresponding to the nodule seen in the right lateral zone of prostate gland. (1.5 Tesla MR images). b)
Apparent diffusion coefficient (ADC) map show a corresponding low intensity focus in the right lateral zone of prostate gland. The hyper-intense signal on DWI and corresponding hypo-
intensity on ADC map represent diffusion restriction. (1.5 Tesla MR images).
The classical MR appearance of prostate cancer is a round
or ill defined, low signal intensity focus (hypo-intense) in
the background of bright peripheral zone tissue. This is
due to loss of normal glandular (ductal) morphology in
prostate cancer6 (Figure-2). 
On T1-weighted images, the tumour is almost
impossible to detect because of homogenous medium
signal intensity with difficulty discerning the zonal
anatomy.4,8 This sequence, however, is useful to detect
the post biopsy haemorrhage, which appears as areas
of high T1 signal intensity due to paramagnetic, iron-
rich, blood by products9 within the otherwise
homogeneous prostate. Blood has low signal intensity
on T2-weighted images, and can either mimic cancer
and/or lead to an inaccurate estimate of its volume4
(Figure-3).
Extra capsular extension (ECE) / Seminal
Vesicle (SV) involvement
The criteria for extra-capsular extension include
asymmetry, bulge of prostate contour, thickening of
neuro-vascular bundle(s), capsular enhancement and
breach, tumour signal in peri-prostatic fat and
obliteration of recto-prostatic angle.4,10,11 On T2WI,
these findings provide a specificity of more than 90%.
The SVs are seen as elongated fluid-filled structures
with thin septae with low signal intensity on T1-
weighted (T1W) images and high signal intensity on
T2W images.12 Combination of tumour at prostate base
extending beyond the capsule and low signal intensity
within SV in the background of high signal fluid on T2-
weighted images are highly predictive of SV invasion.13
The reported sensitivity of MRI scan for the detection of
extra capsular extension is 13-95% with specificity
ranging from 49-97%.14-16
Diffusion-weighted imaging (DWI)
Diffusion-weighted MRI uses principle of Brownian
motion of water molecules in tissues.17,18 It has
advantage of short acquisition time, improved
specificity and no requirement for any specialised
hardware.19
The rate of diffusion of water in soft tissues is lower than
in free solution and is described by the apparent
diffusion coefficient (ADC), which correlates inversely
with tissue cellularity.20 Increased cellularity and loss of
ductal morphology result in restriction of water
diffusion in prostate cancer with corresponding low
signal intensity in ADC Values.20
ADC maps can be calculated on DWI thus enabling
qualitative and quantitative assessment of the
aggressiveness of prostate cancer.6 The ADC values for
malignant tissue are commonly lower than those of
normal gland as well as benign prostatic hyperplasia
(BPH) nodules21-23 (Figure-4).
Limitations
DWI has low spatial resolution and hence lower
accuracy in the assessment of extra-capsular
extension.24 Benign conditions such as prostatitis,
compact fibro muscular stroma seen in BPH25 and organ
motion26 can also lower the ADC and hence give false
positive results. Well-differentiated tumours with
predominantly glandular components can lead to false
negative results.27
Dynamic contrast-enhanced MRI (DCE)
This imaging sequence relies on tumour neo-
angiogenesis.4 Administration of gadolinium-based
contrast is done for enhancing tumour vascularity.3
Early nodular enhancement before the rest of prostate
and early washout of signal intensity is characteristic of
prostate cancer.3
The data generated by DCE MRI is assessed in 3 ways,
i.e. qualitatively, semi-quantitatively and
quantitatively. The former way is applied in routine
clinical practice.4,28 Intensity-time curves are
generated to evaluate time to peak, maximum uptake
slope, peak enhancement and washout rates. The
quantitative approach uses more sophisticated
pharmacokinetic parameters to describe tissue
vascularisation such as mean transit time, blood flow
and permeability surface area.4,29 Jackson et al.30
showed that the sensitivity and specificity of DCE-MRI
(50% and 85%, respectively) is higher than that of T2W
imaging (21% and 81%, respectively).
Limitations
The limiting factors in DCE-MRI are motion and biopsy
artefacts. The rectal motion and patient movements
may lead to noisy curves and distorted low quality
images, therefore, bowel preparation with enema and
anti-peristaltic agents are recommended to overcome
these pitfalls.31
MR Spectroscopy Imaging (MRSI)
MRSI depicts the metabolic profile of the prostatic
tissue.4 Neoplastic proliferation leads to increased
phospholipid cell membrane turnover with resultant
difference in concentration of chemical metabolites.3
This study enables to show lower levels of citrate
(marker of benign tissue) and higher levels of choline
(marker of malignant tissue) from volumes of interest
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(voxels) that encompass prostate cancer.4
MRSI not only detects cancer but also provides
information about the lesion aggressiveness (Gleason
scoring).32 This approach can be used to evaluate the
"metabolic atrophy" after treatment and for the
detection of recurrence after radiation therapy.33 A
sensitivity and specificity as high as 95% and 91%,
respectively, has been reported for MRSI in conjunction
with endo-rectal MRI.34
Limitations
The interpretation of MRSI is challenging. The spatial
resolution is poor and therefore this study is unable to
depict the peri-prostatic area and accurate staging
information.35 It needs additional software for
interpreting the data adding to time and cost.36
MRI-guided prostate biopsy
Contrary to standard set of TRUS-guided prostate
biopsies, MRI-guided prostate biopsy targets only
area(s) considered to be suspicious, hence resulting in
improved accuracy in prostate cancer detection and
localisation, especially for the lesions that are not
routinely targeted on TRUS-guided biopsies such as
anterior tumours.37,38 MRI scan also helps in localising
the site of tumour recurrence after definitive
treatment.39
Role of MRI in planning surgery and follow-
up (surveillance and recurrence)
A safe and effective operation can be guided by
information from MRI imaging leading to oncological
clearance while preserving the peri-prostatic tissues
important for recovery of urinary and sexual function.3
MRI also helps to predict the intra-operative blood
loss. A positive correlation was observed b/w
prominence of apical peri-prostatic veins and
associated blood loss.40
Moreover, mpMRI can also predict functional
outcome after surgery. The length of membranous
urethra on coronal endo-rectal MR image is an
important predictor for urinary incontinence.41
Patients with longer than average (14mm)
membranous urethra experience more rapid return
to complete continence.
MpMRI is helpful in patients with biochemical
recurrence (rising PSA value) without any palpable
tumour in prostatic fossa. The sensitivity and specificity
of endo-rectal MRI to evaluate local recurrence (peri-
anastomotic and retro-vesical region) after
prostatectomy was reported to be 91% and 45%.42
MRI-guided focal therapies
Cryoablation and high-intensity focused ultrasound
(HIFU) are the two contemporary treatment modalities
used as focal therapy. MR-guided targeted focal and
regional therapies are increasingly used for localised
primary (native) and recurrent prostate cancer as well as
for monitoring the effectiveness of these treatments.43
Recently, pre-clinical and phase 1 trials have also
reported real-time MR-guided focal laser ablation
(FLA).44
Reporting and communication of mp-MRI
data (prostate imaging reporting and data
system (PI-RADS) classification)
European Society of Urogenital Radiology (ESUR)
prostate MR guidelines of 2012 recommend structured
reporting system for mp-MRI data, including the
following set of information:6
A) PI-RADS score (probability of cancer risk and its
aggression) 
B) Location and probability of extra-prostatic disease
C) Pertinent incidental findings.
Individual lesion(s) should be given a PI-RADS score on
a five-point scale from 1-5, with a score of "1" denoting
that clinically significant disease was highly unlikely to
be present and a score of "5" denoting that clinically
significant disease was highly likely to be present.45
Grey A.D. et al.46 found PI-RADS system to be a very
good predictor for trans-perineal prostate biopsy
outcome.
Conclusion
Mp-MRI is a rapidly evolving and useful tool for the
diagnosis, localisation and staging of prostate cancer
and to facilitate the targeted therapies. It has the
potential for reduction of unnecessary biopsies and
provides a rapid and accurate diagnosis for both native
and recurrent tumours. It should become an integral
part of prostate cancer risk assessment.
Disclaimer: None.
Conflict of Interest: None.
Source of Funding: None.
References
1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer
J Clin 2014; 64: 9-29.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM.
Estimates of worldwide burden of cancer in 2008: GLOBOCAN
2008. Int J Cancer 2010 ; 127: 2893-917.
J Pak Med Assoc
102 S. M. Nazim, M. H. Ather, B. Salam
3. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT.
Imaging prostate cancer: a multi-disciplinary perspective.
Radiology 2007; 243: 28-53.
4. Costouros NG, Coakley FV, Westphalen AC, Qayyum A, Yeh BM,
Joe BN, et al. Diagnosis of prostate cancer in patients with an
elevated prostate-specific antigen level: role of endorectal MRI
and MR spectroscopic imaging. Am J Roentgenol 2007; 188:
812-6.
5. Ullrich T, Quentin M, Oelers C, Dietzel F, Sawicki LM, Arsov C, et
al. Magnetic resonance imaging of the prostate at 1.5 versus
3.0T: A prospective comparison study of image quality. Eur J
Radiol. 2017 ; 90 :192-197.
6. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S,
Villeirs G, et al; European Society of Urogenital Radiology.ESUR
prostate MR guidelines 2012. Eur Radiol 2012; 22: 746-57.
7. de Rooij M, Hamoen EH, Fütterer JJ, Barentsz JO, Rovers MM.
Accuracy of multiparametric MRI for prostate cancer detection:
a meta-analysis. Am J Roentgenol 2014; 202: 343-51.
8. Bouchelouche K, Turkbey B, Choyke PL. Advances in imaging
modalities in prostate cancer. Curr Opin Oncol. 2015 ; 27 :
224-31.
9. Sharif-Afshar AR, Feng T, Koopman S, Nguyen C, Li Q, Shkolyar
E, et al.  Impact of post prostate biopsy hemorrhage on
multiparametric magnetic resonance imaging. Can J Urol. 2015
; 22 :7698-702.
10. Somford DM, Hamoen EH, Fütterer JJ, van Basten JP,
Hulsbergen-van de Kaa CA, Vreuls W, et al. The predictive value
of endorectal 3 Tesla multiparametric magnetic resonance
imaging for extraprostatic extension in patients with low,
intermediate and high risk prostate cancer.  J Urol. 2013 ;190 :
1728-34. 
11. Outwater EK, Petersen RO, Siegelman ES, Gomella LG,
Chernesky CE, Mitchell DG. Prostate carcinoma: assessment of
diagnostic criteria for capsular penetration on endorectal coil
MR images. Radiology 1994; 193: 333-9.
12. Hedgire SS, Oei TN, McDermott S, Cao K, Patel M Z, Harisinghani
MG. Multiparametric magnetic resonance imaging of prostate
cancer.Indian J Radiol Imaging  2012; 22: 160-9.
13. Soylu FN, Peng Y, Jiang Y, Wang S, Schmid-Tannwald C, Sethi I,
et al. Seminal vesicle invasion in prostate cancer: evaluation by
using multiparametric endorectal MR imaging. Radiology. 2013
; 267 :797-806.
14. Krishna S, Lim CS, McInnes MD, Flood TA, Shabana WM, Lim RS,
et al. Evaluation of MRI for diagnosis ofextraprostatic extension
in prostate cancer.J Magn Reson Imaging. 2017 Apr 7. doi:
10.1002/jmri.25729. 
15. de Cobelli O, Terracciano D, Tagliabue E, Raimondi S, Bottero D,
Cioffi A, et al. Predicting Pathological Features at Radical
Prostatectomy in Patients with Prostate Cancer Eligible for
Active Surveillance by Multiparametric Magnetic Resonance
Imaging. PLoS One. 2015;10:e0139696. 
16. Hara T, Nakanishi H, Nakagawa T, Komiyama M, Kawahara T,
Manabe T, et al. Ability of preoperative 3.0-Tesla magnetic
resonance imaging to predict the absence of side-specific
extracapsular extension of prostate cancer. Int J Urol. 2013 ; 20
:993-9.
17. Maurer MH, Härmä KH, Thoeny H. Diffusion-Weighted
Genitourinary Imaging. Radiol Clin North Am. 2017 ; 55 :393-
411.
18. Mazaheri Y, Vargas HA, Akin O, Goldman DA, Hricak H. Reducing
the influence of b-value selection on diffusion-weighted
imaging of the prostate: evaluation of a revised mono
exponential model within a clinical setting. J Magn Reson
Imaging 2012; 35: 660-8.
19. Miao H, Fukatsu H, Ishigaki T. Prostate cancer detection with 3-
T MRI: comparison of diffusion-weighted and T2-weighted
imaging. Eur J Radiol 2007; 61: 297-302.
20. Zelhof B, Lowry M, Rodrigues G, Kraus S, Turnbull L. Description
of magnetic resonance imaging-derived enhancement
variables in pathologically confirmed prostate cancer and
normal peripheral zone regions. BJU Int 2009; 104: 621-7.
21. Sato C, Naganawa S, Nakamura T, Kumada H, Miura S, Takizawa
O, et al. Differentiation of noncancerous tissue and cancer
lesions by apparent diffusion coefficient values in transition
and peripheral zones of the prostate. J Magn Reson Imaging
2005; 21: 258-62.
22. Simpkin CJ, Morgan VA, Giles SL, Riches SF, Parker C, deSouza
NM. Relationship between T2 relaxation and apparent diffusion
coefficient in malignant and non-malignant prostate regions
and the effect of peripheral zone fractional volume. Br J Radiol.
2013; 86 :20120469. 
23. Ren J, Huan Y, Li F, Wang H, Ge Y, Chang Y, et al. Combined T2-
weighted and diffusion-weighted MRI for diagnosis of urinary
bladder invasion in patients with prostate carcinoma. J Magn
Reson Imaging 2009; 30: 351-6.
24. Kim W, Kim CK, Park JJ, Kim M, Kim JH. Evaluation of
extracapsular extension in prostate cancer using qualitative
and quantitative multiparametric MRI. J Magn Reson Imaging.
2017 ; 45 :1760-70.
25. Xu J, Humphrey PA, Kibel AS, Snyder AZ, Narra VR, Ackerman JJ,
et al. Magnetic resonance diffusion characteristics of
histologically defined prostate cancer in humans. Magn Reson
Med 2009; 61: 842-50.
26. Lim HK, Kim JK, Kim KA, Cho KS. Prostate cancer: apparent
diffusion coefficient map with T2-weighted images for
detection--a multireader study. Radiology 2009; 250: 145-51.
27. Woo S, Cho JY, Kim SY, Kim SH. Extracapsular extension in
prostate cancer: added value of diffusion-weighted MRI in
patients with equivocal findings on T2-weighted imaging. AJR
Am J Roentgenol. 2015 ; 204 :W168-75.
28. Engelbrecht MR, Huisman HJ, Laheij RJ, Jager GJ, van Leenders
GJ, Hulsbergen-Van De Kaa CA, et al. Discrimination of prostate
cancer from normal peripheral zone and central gland tissue by
using dynamic contrast-enhanced MR imaging. Radiology
2003; 229: 248-54.
29. Li X, Cai Y, Moloney B, Chen Y, Huang W, Woods M, et al. Relative
sensitivities of DCE-MRI pharmacokinetic parameters to arterial
input function (AIF) scaling. J Magn Reson. 2016 ; 269 :104-12.
30. Jackson AS, Reinsberg SA, Sohaib SA, Charles-Edwards EM,
Jhavar S, Christmas TJ, et al. Dynamic contrast-enhanced MRI
for prostate cancer localization. Br J Radiol 2009; 82: 148-56.
31. McMahon CJ, Bloch BN, Lenkinski RE, Rofsky NM. Dynamic
contrast-enhanced MR imaging in the evaluation of patients
with prostate cancer. Magn Reson Imaging Clin N Am 2009; 17:
363-83.
32. Kobus T, van der Laak JA, Maas MC, Hambrock T, Bruggink CC,
Hulsbergen-van de Kaa CA, et al. Contribution of
Histopathologic Tissue Composition to Quantitative MR
Spectroscopy and Diffusion-weighted Imaging of the Prostate.
Radiology. 2016 ; 278: 801-11. 
33. Panebianco V, Barchetti F, Musio D, Forte V, Pace A, De Felice F,
et al.  Metabolic atrophy and 3-T 1H-magnetic resonance
spectroscopy correlation after radiation therapy for prostate
cancer. BJU Int. 2014 ;114 :852-9.
34. Jagannathan D, Indiran V. Accuracy of Diffusion Weighted
Images and MR Spectroscopy in Prostate Lesions - Our
Experience with Endorectal Coil on 1.5 T MRI. J Clin Diagn Res.
2017 ; 11 :TC10-TC14.
35. Mazaheri Y, Shukla-Dave A, Hricak H, Fine SW, Zhang J,
Inurrigarro G, et al. Prostate cancer: identification with
Vol. 68, No. 1, January 2018
Role of multi-parametric (mp) MRI in prostate cancer 103
combined diffusion-weighted MR imaging and 3D 1H MR
spectroscopic imaging--correlation with pathologic findings.
Radiology 2008; 246: 480-8.
36. Choi YJ, Kim JK, Kim N, Kim KW, Choi EK, Cho KS. Functional MR
imaging of prostate cancer. Radiographics 2007; 27: 63-75.
37. Yacoub JH, Verma S, Moulton JS, Eggener S, Aytekin O. Imaging-
guided prostate biopsy: conventional and emerging
techniques. Radiographics 2012; 32: 819-37.
38. Fütterer JJ, Barentsz JO. MRI-guided and robotic-assisted
prostate biopsy. Curr Opin Urol. 2012; 22: 316-9.
39. Kitajima K, Murphy RC, Nathan MA, Froemming AT, Hagen CE,
Takahashi N, et al.  Detection of recurrent prostate cancer after
radical prostatectomy: comparison of 11C-choline PET/CT with
pelvic multiparametric MR imaging with endorectal coil. J Nucl
Med. 2014 ; 55 :223-32.
40. Coakley FV, Eberhardt S, Wei DC, Wasserman ES, Heinze SB,
Scardino PT, et al. Blood loss during radical retropubic
prostatectomy: relationship to morphologic features on
preoperative endorectal magnetic resonance imaging. Urology
2002; 59: 884-8.
41. Coakley FV, Eberhardt S, Kattan MW, Wei DC, Scardino PT,
Hricak H. Urinary continence after radical retropubic
prostatectomy: relationship with membranous urethral length
on preoperative endorectal magnetic resonance imaging. J
Urol 2002; 168: 1032-5.
42. Linder BJ, Kawashima A, Woodrum DA, Tollefson MK, Karnes J,
Davis BJ, et al. Early localization of recurrent prostate cancer
after prostatectomy by endorectal coil magnetic resonance
imaging. Can J Urol 2014; 21: 7283-9.
43. Woodrum DA, Kawashima A, Gorny KR, Mynderse LA. Magnetic
Resonance-Guided Thermal Therapy for Localized and
Recurrent Prostate Cancer. Magn Reson Imaging Clin N Am
2015; 23: 607-19.
44. Natarajan S, Raman S, Priester AM, Garritano J, Margolis DJ, Lieu
P, et al. Focal Laser Ablation of Prostate Cancer: Phase I Clinical
Trial. J Urol  2016; 196: 68-75.
45. Bomers JG, Barentsz JO. Standardization of multiparametric
prostate MR imaging using PI-RADS. Biomed Res Int 2014;
Article ID 431680.
46. Grey AD, Chana MS, Popert R, Wolfe K, Liyanage SH, Acher PL.
Diagnostic accuracy of magnetic resonance imaging (MRI)
prostate imaging reporting and data system (PI-RADS) scoring
in a transperineal prostate biopsy setting. BJU Int 2015; 115:
728-35.
J Pak Med Assoc
104 S. M. Nazim, M. H. Ather, B. Salam
